Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria
NCT04369352 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150
Last updated 2023-03-28
Summary
Various treatment options exist for patients with platinum-sensitive relapsed epithelial ovarian cancer (ROC).
The register will provide an overview of chosen treatments including the reasons, why these options were chosen.
Conditions
- Recurrent Ovarian Carcinoma
Sponsors & Collaborators
-
Medical University Innsbruck
lead OTHER
Principal Investigators
-
Lukas Hefler, Prim. Dr. · Ordensklinikum Linz
Eligibility
- Min Age
- 18 Years
- Max Age
- 99 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-08-09
- Primary Completion
- 2024-12-31
- Completion
- 2025-08-31
Countries
- Austria
Study Locations
More Related Trials
-
BRCA 1/2 Status as a Predictive Factor to Response to Platinum Based Chemotherapy in Cancer Ovary
NCT06304922 ·Status: NOT_YET_RECRUITING
-
Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced Endometrial Carcinoma
NCT01460979 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
NCT04931342 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
NCT03690739 ·Status: TERMINATED ·Phase: PHASE3
-
IPHC in Patients With Platinum-sensitive Recurrent Ovarian Cancer
NCT01588964 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer
NCT02900560 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Predictive Factors of Chemoresistance in Ovarian Cancer
NCT02878122 ·Status: COMPLETED
-
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
NCT04566952 ·Status: UNKNOWN ·Phase: PHASE2
-
Oxaliplatin in Treating Patients With Recurrent or Refractory Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Has Not Responded to Platinum- Based Chemotherapy
NCT00005836 ·Status: COMPLETED ·Phase: PHASE2
-
Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer
NCT03949283 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Reinduction Chemotherapy Containing Carboplatin and Paclitaxel With or Without Epoetin Alpha in Recurrent Platinum Sensitive Ovarian Cancer, Cancer of the Fallopian Tube or Peritoneum
NCT00189371 ·Status: TERMINATED ·Phase: PHASE3
-
Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel
NCT01332656 ·Status: COMPLETED ·Phase: PHASE2
-
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer
NCT00466986 ·Status: COMPLETED ·Phase: PHASE2
-
Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer
NCT01372787 ·Status: UNKNOWN
-
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
NCT02432378 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
NCT04152941 ·Status: COMPLETED
-
Dose-finding Study in Platinum-Resistant Ovarian Cancer
NCT01653912 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Hycamtin Plus Carboplatin Versus Established Regimens for the Treatment of Ovarian Cancer Relapse
NCT00437307 ·Status: COMPLETED ·Phase: PHASE3
-
Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study
NCT00968799 ·Status: TERMINATED ·Phase: NA
-
Patient Reported Symptoms in Ovarian Cancer (PRECISION)
NCT01422265 ·Status: COMPLETED
-
Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients
NCT01124435 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT03776812 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
NCT04575961 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study to Evaluate the Effect of the Combination of Pertuzumab With Carboplatin-Based Standard Chemotherapy in Patients With Recurrent Ovarian Cancer
NCT02004093 ·Status: COMPLETED ·Phase: PHASE2
-
Immuno Monitoring in Patient With Epithelial Ovarian Cancer Eligible to PARP Inhibitors
NCT04675320 ·Status: UNKNOWN